Latest Headlines

  1. Queen Mary Trials New Approach To Drug Development For Rare Diseases 9/11/2025

    Developing disease modifying therapies for rare diseases is extremely challenging. It’s clinically difficult due to the small cohort sizes, and it’s difficult to raise investment as the market may not be big enough to cover the costs.

  2. GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform To Transform Precision Medicine And Drug Development 9/11/2025

    GNQ Insilico Inc. (“GNQ” or “the Company”), a pioneering TechBio firm leveraging exponential technologies for precision medicine, announces the official launch of its groundbreaking deep tech Drug Assessment Platform (DAP).

  3. Symeres Acquires DGr Pharma To Enhance Regulatory Expertise And Broaden Its Biopharma Capabilities 9/10/2025

    Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.

  4. Lilly Launches TuneLab Platform To Give Biotechnology Companies Access To AI-Enabled Drug Discovery Models Built Through Over $1B In Research Investment 9/9/2025

    Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data.

  5. XtalPi AI Drug Discovery Collaboration Reaches Milestone As PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals 9/9/2025

    XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors.

  6. insitro Partners With Lilly To Build First-In-Kind Machine Learning Models To Advance Small Molecule Drug Discovery 9/9/2025

    insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.

  7. Teva's Emrusolmin Granted U.S. FDA Fast Track Designation For Treatment Of Multiple System Atrophy 9/9/2025

    Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Teva’s investigational therapy emrusolmin (TEV-56286) for the treatment of Multiple System Atrophy (MSA).

  8. New UMaine Research Could Help Lower Prescription Drug Costs 9/8/2025

    One of the main factors driving prices in pharmaceuticals, such as cholesterol-lowering drugs and antibiotics, is the cost of production and materials.

  9. Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development 9/4/2025

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability.

  10. Karmanos Researcher Co-Discovered Compound, Led To First FDA-Approved Therapy For Rare Brain Cancer 9/4/2025

    For Gen Sheng Wu, Ph.D., a member of the Molecular Therapeutics Research Program at the Barbara Ann Karmanos Cancer Institute and professor in the Department of Oncology and Pathology at Wayne State University School of Medicine, witnessing the research he began 20 years ago lead to a newly approved cancer treatment is a dream come true.